Chi-Chung Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chi-Chung Li has a total of 253 co-authors. Here are the top co-authors by number of shared publications:
- Brendan C. Bender
Genentech Inc., South San Francisco, California
12 shared publications - David C. Turner
Clinical Pharmacology Genentech South San Francisco California USA
12 shared publications - Anton Belousov
F. Hoffmann-La Roche Ltd, Basel, Switzerland
10 shared publications - Kendra K. Radtke
Genentech Inc., South San Francisco, California
10 shared publications - Sumedha Roy
Genentech Inc., South San Francisco, California
10 shared publications - Zao Li
Genentech Inc., South San Francisco, California
10 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Clinical Pharmacology of Cytokine Release Syndrome with T-Cell–Engaging Bispecific Antibodies: Current Insights and Drug Development Strategies
Summary of CRS Occurrence by Step-Up Dose Fractions for Approved T-Cell Engaging Bispecific Antibodies (T-BiSp)
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Clinical Pharmacology of Cytokine Release Syndrome with T-Cell–Engaging Bispecific Antibodies: Current Insights and Drug Development Strategies
Summary of CRS Occurrence by Step-Up Dose Fractions for Approved T-Cell Engaging Bispecific Antibodies (T-BiSp)
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Clinical Pharmacology of Cytokine Release Syndrome with T-Cell–Engaging Bispecific Antibodies: Current Insights and Drug Development Strategies
Selected Cytokine Concentration-Time Profiles for Approved T-Cell Engaging Bispecific Antibodies (T-BiSp)
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Clinical Pharmacology of Cytokine Release Syndrome with T-Cell–Engaging Bispecific Antibodies: Current Insights and Drug Development Strategies
Selected Cytokine Concentration-Time Profiles for Approved T-Cell Engaging Bispecific Antibodies (T-BiSp)
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Clinical Pharmacology of Cytokine Release Syndrome with T-Cell–Engaging Bispecific Antibodies: Current Insights and Drug Development Strategies
Overview of CRS Occurrence, Dosing Regimens, and Exposure Metrics for Exposure-Response Analyses of T-Cell Engaging Bispecific Antibodies (T-BiSp)
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Clinical Pharmacology of Cytokine Release Syndrome with T-Cell–Engaging Bispecific Antibodies: Current Insights and Drug Development Strategies
Overview of CRS Occurrence, Dosing Regimens, and Exposure Metrics for Exposure-Response Analyses of T-Cell Engaging Bispecific Antibodies (T-BiSp)
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Clinical Pharmacology of Cytokine Release Syndrome with T-Cell–Engaging Bispecific Antibodies: Current Insights and Drug Development Strategies
Overview of T-Cell Engaging Bispecific Antibodies (T-BiSp): Molecule Format, Dosing Schedule, Hospitalization, and Premedication
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Clinical Pharmacology of Cytokine Release Syndrome with T-Cell–Engaging Bispecific Antibodies: Current Insights and Drug Development Strategies
Overview of T-Cell Engaging Bispecific Antibodies (T-BiSp): Molecule Format, Dosing Schedule, Hospitalization, and Premedication
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Clinical Pharmacology of Cytokine Release Syndrome with T-Cell–Engaging Bispecific Antibodies: Current Insights and Drug Development Strategies
Cytokine release syndrome (CRS) is a common acute toxicity in T-cell therapies, including T-cell–engaging bispecific antibodies (T-BiSp). Effective CRS management and prevention are crucial in T-BiSp development. Required hospitalization for seven of the nine approved T-BiSp and the need for clinical intervention in severe cases highlight the importance of mitigation strategies to reduce health care burden and improve patient outcomes. In this review, we discuss the emerging evidence on CRS mitigation, management, and prediction. We cover different strategies for dose optimization, current and emerging (pre) treatment strategies, quantitative pharmacology tools used during drug development, and biomarkers and predictive factors. Insights are gleaned on step-up dosing and formulation effects on CRS and CRS relationships with cytokine dynamics and drug levels gathered through a review of T-BiSp licensing applications and emerging data from conferences and publications.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Clinical Pharmacology of Cytokine Release Syndrome with T-Cell–Engaging Bispecific Antibodies: Current Insights and Drug Development Strategies
Cytokine release syndrome (CRS) is a common acute toxicity in T-cell therapies, including T-cell–engaging bispecific antibodies (T-BiSp). Effective CRS management and prevention are crucial in T-BiSp development. Required hospitalization for seven of the nine approved T-BiSp and the need for clinical intervention in severe cases highlight the importance of mitigation strategies to reduce health care burden and improve patient outcomes. In this review, we discuss the emerging evidence on CRS mitigation, management, and prediction. We cover different strategies for dose optimization, current and emerging (pre) treatment strategies, quantitative pharmacology tools used during drug development, and biomarkers and predictive factors. Insights are gleaned on step-up dosing and formulation effects on CRS and CRS relationships with cytokine dynamics and drug levels gathered through a review of T-BiSp licensing applications and emerging data from conferences and publications.
- 1 May 2026
- Published by Springer Nature
- Vol. 2997, 205-220
Overview of Quantitative Clinical Pharmacology for T-Cell Engaging Bispecific Antibodies
T-cell bispecific antibodies (TCBs) are an exciting advancement in cancer immunotherapy, enabling potent and durable tumor responses by bridging CD3-positive T cells with tumor-specific antigens. By forming artificial immune synapses, TCBs activate T cells in an MHC-independent manner, initiating robust anti-tumor responses. However, these unique mechanisms present challenges, including complex pharmacokinetics (PK), target-mediated drug disposition (TMDD), and on-target toxicities such as cytokine release syndrome (CRS) and off-tumor effects. This chapter offers a comprehensive review of the clinical pharmacology considerations involved in TCB development, covering their mechanisms of action, PK and pharmacodynamic (PD) characteristics, and bioanalytical strategies. It also summarizes approaches to mitigate risks and optimize therapeutic outcomes.Advanced modeling techniques, such as quantitative systems pharmacology (QSP) and physiologically based pharmacokinetics (PBPK) modeling, are highlighted as valuable tools for addressing translational challenges. When combined with emerging applications of artificial intelligence and machine learning, these methods can provide further predictability and insights for optimizing dosing regimens, mitigating toxicities, and predicting clinical outcomes. The chapter also discusses strategies for overcoming resistance mechanisms through combination therapies and improving TCB constructs to enhance patient benefit. By integrating these insights, the chapter emphasizes the role of pharmacology and modeling advances in maximizing the therapeutic potential of TCBs for cancer treatment.
- 1 May 2026
- Published by Springer Nature
- Vol. 2997, 205-220
Overview of Quantitative Clinical Pharmacology for T-Cell Engaging Bispecific Antibodies
T-cell bispecific antibodies (TCBs) are an exciting advancement in cancer immunotherapy, enabling potent and durable tumor responses by bridging CD3-positive T cells with tumor-specific antigens. By forming artificial immune synapses, TCBs activate T cells in an MHC-independent manner, initiating robust anti-tumor responses. However, these unique mechanisms present challenges, including complex pharmacokinetics (PK), target-mediated drug disposition (TMDD), and on-target toxicities such as cytokine release syndrome (CRS) and off-tumor effects. This chapter offers a comprehensive review of the clinical pharmacology considerations involved in TCB development, covering their mechanisms of action, PK and pharmacodynamic (PD) characteristics, and bioanalytical strategies. It also summarizes approaches to mitigate risks and optimize therapeutic outcomes.Advanced modeling techniques, such as quantitative systems pharmacology (QSP) and physiologically based pharmacokinetics (PBPK) modeling, are highlighted as valuable tools for addressing translational challenges. When combined with emerging applications of artificial intelligence and machine learning, these methods can provide further predictability and insights for optimizing dosing regimens, mitigating toxicities, and predicting clinical outcomes. The chapter also discusses strategies for overcoming resistance mechanisms through combination therapies and improving TCB constructs to enhance patient benefit. By integrating these insights, the chapter emphasizes the role of pharmacology and modeling advances in maximizing the therapeutic potential of TCBs for cancer treatment.
- Open Access
- 22 December 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (1) , 12
Correction: Susilo et al. Whole-Body Physiologically Based Pharmacokinetic Modeling Framework for Tissue Target Engagement of CD3 Bispecific Antibodies. Pharmaceutics 2025, 17, 500
- 22 December 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (1) , 12
Open AccessCorrection: Susilo et al. Whole-Body Physiologically Based Pharmacokinetic Modeling Framework for Tissue Target Engagement of CD3 Bispecific Antibodies. Pharmaceutics 2025, 17, 500
- Open Access
- 25 April 2025
- Published by Wiley in Clinical and Translational Science
- Vol. 18 (5) , e70211
Ethnic Sensitivity Assessment of Mosunetuzumab Pharmacokinetics and Pharmacodynamics in Chinese Patients With Relapsed or Refractory Follicular Lymphoma
Mosunetuzumab, a CD20 × CD3 T‐cell‐engaging bispecific antibody, redirects T cells to eliminate malignant B cells. The purpose of YO43555 was to assess the pharmacokinetics (PK), safety, tolerability, and efficacy of mosunetuzumab as a single agent in Chinese patients with relapsed/refractory follicular lymphoma (R/R FL). The impact of ethnicity/region on the PK disposition of mosunetuzumab was assessed by non‐compartmental analysis (NCA) as well as a population PK (popPK) approach. A previously established popPK model for intravenous mosunetuzumab, built from the global Phase I/II study GO29781, was externally validated with the PK data from study YO43555. Results from the PK analysis showed that the global popPK model adequately captured the individual PK of the Chinese population. The model predicted mosunetuzumab exposure metrics in Chinese patients were similar to those observed in Asian patients in the GO29781 R/R FL subpopulation with the same dose regimen, while the exposure differences between Chinese and Non‐Asians from the global population were < 20%. An overlay of the exposure levels for Chinese patients on the established E‐R relationship in global patients indicated that the mosunetuzumab exposure of Chinese patients remained within the established bounds for clinical safety and efficacy. The cytokine biomarkers IL‐6 and TNF‐α showed similar time‐course patterns of release as observed in globally enrolled patients. In summary, mosunetuzumab PK disposition did not show significant ethnic sensitivity that would impact patient outcomes. Therefore, dose adjustment of the globally approved mosunetuzumab regimen is not warranted for Chinese patients with R/R FL.Trial Registration: ClinicalTrials.gov identifier: NCT02500407
- 25 April 2025
- Published by Wiley in Clinical and Translational Science
- Vol. 18 (5) , e70211
Open AccessEthnic Sensitivity Assessment of Mosunetuzumab Pharmacokinetics and Pharmacodynamics in Chinese Patients With Relapsed or Refractory Follicular Lymphoma
Mosunetuzumab, a CD20 × CD3 T‐cell‐engaging bispecific antibody, redirects T cells to eliminate malignant B cells. The purpose of YO43555 was to assess the pharmacokinetics (PK), safety, tolerability, and efficacy of mosunetuzumab as a single agent in Chinese patients with relapsed/refractory follicular lymphoma (R/R FL). The impact of ethnicity/region on the PK disposition of mosunetuzumab was assessed by non‐compartmental analysis (NCA) as well as a population PK (popPK) approach. A previously established popPK model for intravenous mosunetuzumab, built from the global Phase I/II study GO29781, was externally validated with the PK data from study YO43555. Results from the PK analysis showed that the global popPK model adequately captured the individual PK of the Chinese population. The model predicted mosunetuzumab exposure metrics in Chinese patients were similar to those observed in Asian patients in the GO29781 R/R FL subpopulation with the same dose regimen, while the exposure differences between Chinese and Non‐Asians from the global population were < 20%. An overlay of the exposure levels for Chinese patients on the established E‐R relationship in global patients indicated that the mosunetuzumab exposure of Chinese patients remained within the established bounds for clinical safety and efficacy. The cytokine biomarkers IL‐6 and TNF‐α showed similar time‐course patterns of release as observed in globally enrolled patients. In summary, mosunetuzumab PK disposition did not show significant ethnic sensitivity that would impact patient outcomes. Therefore, dose adjustment of the globally approved mosunetuzumab regimen is not warranted for Chinese patients with R/R FL.Trial Registration: ClinicalTrials.gov identifier: NCT02500407
- Open Access
- 9 April 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (4) , 500
Whole-Body Physiologically Based Pharmacokinetic Modeling Framework for Tissue Target Engagement of CD3 Bispecific Antibodies
Background: T-cell-engaging bispecific (TCB) antibodies represent a promising therapy that utilizes T-cells to eliminate cancer cells independently of the major histocompatibility complex. Despite their success in hematologic cancers, challenges such as cytokine release syndrome (CRS), off-tumor toxicity, and resistance limit their efficacy in solid tumors. Optimizing biodistribution is key to overcoming these challenges. Methods: A physiologically based pharmacokinetic (PBPK) model was developed that incorporates T-cell transmigration, retention, receptor binding, receptor turnover, and cellular engagement. Preclinical biodistribution data were modeled using two TCB formats: one lacking tumor target binding and another with target arm binding, each with varying CD3 affinities in a transgenic tumor-bearing mouse model. Results: The PBPK model successfully described the distribution of activated T-cells and various TCB formats. It accurately predicted preclinical biodistribution patterns, demonstrating that higher CD3 affinity leads to faster clearance from the blood and increased accumulation in T-cell-rich organs, often reducing tumor exposure. Simulations of HER2-CD3 TCB doses (0.1 µg to 100 mg) revealed monotonic increases in synapse AUC within the tumor. A bell-shaped dose-Cmax relationship for synapse formation was observed, and Tmax was delayed at higher doses. Blood PK was a reasonable surrogate for tumor synapse at low doses but less predictive at higher doses. Conclusions: We developed a whole-body PBPK model to simulate the biodistribution of T-cells and TCB molecules. The insights from this model provide a comprehensive understanding of the factors affecting PK, synapse formation, and TCB activity, aiding in dose optimization and the design of effective therapeutic strategies.
- 9 April 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (4) , 500
Open AccessWhole-Body Physiologically Based Pharmacokinetic Modeling Framework for Tissue Target Engagement of CD3 Bispecific Antibodies
Background: T-cell-engaging bispecific (TCB) antibodies represent a promising therapy that utilizes T-cells to eliminate cancer cells independently of the major histocompatibility complex. Despite their success in hematologic cancers, challenges such as cytokine release syndrome (CRS), off-tumor toxicity, and resistance limit their efficacy in solid tumors. Optimizing biodistribution is key to overcoming these challenges. Methods: A physiologically based pharmacokinetic (PBPK) model was developed that incorporates T-cell transmigration, retention, receptor binding, receptor turnover, and cellular engagement. Preclinical biodistribution data were modeled using two TCB formats: one lacking tumor target binding and another with target arm binding, each with varying CD3 affinities in a transgenic tumor-bearing mouse model. Results: The PBPK model successfully described the distribution of activated T-cells and various TCB formats. It accurately predicted preclinical biodistribution patterns, demonstrating that higher CD3 affinity leads to faster clearance from the blood and increased accumulation in T-cell-rich organs, often reducing tumor exposure. Simulations of HER2-CD3 TCB doses (0.1 µg to 100 mg) revealed monotonic increases in synapse AUC within the tumor. A bell-shaped dose-Cmax relationship for synapse formation was observed, and Tmax was delayed at higher doses. Blood PK was a reasonable surrogate for tumor synapse at low doses but less predictive at higher doses. Conclusions: We developed a whole-body PBPK model to simulate the biodistribution of T-cells and TCB molecules. The insights from this model provide a comprehensive understanding of the factors affecting PK, synapse formation, and TCB activity, aiding in dose optimization and the design of effective therapeutic strategies.
- Open Access
- 17 January 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Clinical Pharmacology of Cytokine Release Syndrome with T-Cell–Engaging Bispecific Antibodies: Current Insights and Drug Development Strategies
Selected Cytokine Concentration-Time Profiles for Approved T-Cell Engaging Bispecific Antibodies (T-BiSp)
- 17 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Clinical Pharmacology of Cytokine Release Syndrome with T-Cell–Engaging Bispecific Antibodies: Current Insights and Drug Development Strategies
Selected Cytokine Concentration-Time Profiles for Approved T-Cell Engaging Bispecific Antibodies (T-BiSp)